on NFL BIOSCIENCES (EPA:ALNFL)
NFL Biosciences Expands Clinical Leadership Amid NFL-101 Development
NFL Biosciences, a biopharmaceutical innovator in botanical medicines for addiction treatment, has announced the expansion of Dr. Yannick Plétan's role as Chief Medical Officer. This enhancement supports the accelerated development of NFL-101, their smoking cessation treatment, as the company gears up for its Phase 3 study.
Dr. Yannick Plétan, affiliated with NFL Biosciences since 2018, brings extensive experience from senior roles at major pharmaceutical firms and was central in developing smoking cessation aids like the nicotine patch. His expanded duties are set to enhance the company's medical and regulatory strategies without increasing costs significantly.
CEO Bruno Lafont highlighted Dr. Plétan's pivotal contributions at a crucial juncture for NFL-101. Meanwhile, Dr. Plétan expressed his commitment to advancing this promising, side-effect-free treatment, enhancing options for those battling tobacco addiction.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NFL BIOSCIENCES news